Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.73 |
| ▸ | DPP4 | P27487 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.73 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.73 |
| ▸ | GAPDH | P04406 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | STAT6 | P42226 | 1/20 | 0.73 |
| ▸ | PI4KA | P42356 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.73 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.73 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10786307 | 0.95 | ADORA1 (0.72) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8328542 | 0.94 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL6828798 | 0.91 | ADORA1 (0.70) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL2534140 | 0.90 | EHMT1 (0.70) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL4581742 | 0.89 | P2RY1 (0.70) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8671037 | 0.89 | EHMT1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL10605538 | 0.89 | ADORA1 (0.66) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL29936475 | 0.89 | EHMT1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8671033 | 0.89 | EHMT1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL873362 | 0.88 | ADORA3 (0.72) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150767-A1 | SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-05-09 | — | — | US | claimed |
| EP-4363588-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals Inc. (US) | 2024-05-08 | — | — | EP | claimed |
| US-20240132895-A1 | GLYCOGEN SYNTHASE KINASE 3 ALPHA (GSK3 ALPHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-04-25 | — | — | US | claimed |
| US-20240124882-A1 | PRION PROTEIN (PRNP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-04-18 | — | — | US | claimed |
| EP-4347822-A2 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-02-29 | — | — | US | claimed |
| EP-4314296-A2 | HUNTINGTIN (HTT) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| US-20240011032-A1 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | BANK OF AMERICA, N.A. | 2024-01-11 | — | — | US | claimed |
| EP-4298220-A1 | PRION PROTEIN (PRNP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-11859185-B2 | Glucokinase (GCK) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | claimed |
| US-20180195073-A1 | GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2018-07-12 | — | — | US | claimed |
| EP-3283631-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2018-02-21 | — | — | EP | claimed |
| EP-3221451-A1 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2017-09-27 | — | — | EP | claimed |
| US-20170260527-A1 | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2017-09-14 | — | — | US | claimed |
| WO-2017100542-A1 | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | WO | claimed |
| WO-2016209862-A1 | GLUCOKINASE (GCK) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-12-29 | — | — | WO | claimed |
| WO-2016168286-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | WO | claimed |
| WO-2016081444-A9 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-21 | — | — | WO | claimed |
| WO-2016081444-A1 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | claimed |
| US-8008060-B2 | Method for growing Cordyceps sinensis on a substrate | Aloha Medicinals Inc. (US) | 2011-08-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195073-A1 | GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | GCKR, GCK, GBA3 | ADORA1 2012/4885SMN1; SMN2 893/4885ADORA3 1943/4885 |
| US-20240011032-A1 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | SNCA, SYNCRIP, PARK7 | ADORA1 1365/4885SMN1; SMN2 20/4885ADORA3 1323/4885 |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | DPP4, DPP3, DPP7 | ADORA1 2442/4885SMN1; SMN2 2997/4885ADORA3 1513/4885 |
| US-20240150767-A1 | SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES | SOD1, SOD3, SMN1; SMN2 | ADORA1 1554/4885SMN1; SMN2 3/4885ADORA3 2179/4885 |
| US-11859185-B2 | Glucokinase (GCK) iRNA compositions and methods of use thereof | GCKR, GCK, GBA3 | ADORA1 2012/4885SMN1; SMN2 893/4885ADORA3 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.